Gene set-level network analysis using a toxicogenomics database  by Kiyosawa, Naoki et al.
Genomics 96 (2010) 39–49
Contents lists available at ScienceDirect
Genomics
j ourna l homepage: www.e lsev ie r.com/ locate /ygenoGene set-level network analysis using a toxicogenomics database
Naoki Kiyosawa a,⁎, Sunao Manabe b, Atsushi Sanbuissho a, Takashi Yamoto a
a Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., 717 Horikoshi, Fukuroi, Shizuoka 437-0065, Japan
b Global Project Management Department, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa, Tokyo 140-8710, JapanAbbreviations: PCC, partial correlation coefﬁcien
cycloheximide; TGx, toxicogenomics; TGP, Toxicogen
relevance network; GGM, Gaussian graphical model; BN
Toxicogenomics Project-Genomics Assisted Toxicity Eva
⁎ Corresponding author. Fax: +81 538 42 4350.
E-mail address: kiyosawa.naoki.wr@daiichisankyo.co
0888-7543/$ – see front matter © 2010 Elsevier Inc. A
doi:10.1016/j.ygeno.2010.03.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 21 January 2010
Accepted 29 March 2010
Available online 2 April 2010
Keywords:
Toxicogenomics
Microarray
Liver
Biomarker
Network
Systems BiologyToxicogenomics data sets on rat livers covering 118 compounds were subjected to inference of a gene set-
level, not individual gene-level, network structure. Expression changing levels for 58 gene sets was used for
network inference with a Gaussian graphical model algorithm. The established network contained
reasonable relationships, such as ones between the blood glucose level and glycolysis-related genes or the
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inference successfully highlighted biological pathway-level interactions. In addition, the robustness of the
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where the gene set-level activation exhibited time-dependent propagation through neighbored nodes (i.e.
gene sets) on the network, indicating that the network structure was robust and comparable with an
external microarray data set. Accumulating such robust gene sets with toxicity-associated subnetwork
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Toxicogenomics (TGx), a comprehensive gene expression analysis
together with a conventional toxicology data set such as blood
chemistry, hematology, organ weights and histopathologic ﬁndings, is
a widely utilized scientiﬁc discipline for both basic and applied
toxicology. In the drug development process, the application of TGx
research is expected to be of use in both characterizing the molecular
mechanisms of toxicities and in early evaluation of the toxic risk
potential of drug candidate compounds [1]. In particular, the
prediction of drug-elicited toxicity in the early stages of drug
development is one of the most promising applications of TGx. It
was estimated that a 10% improvement in predicting future
developmental failure in the clinical phase would save 100 million
dollars of R&D cost per drug [2]. A number of gene sets whose
expression levels are closely associated with certain toxicological
endpoints, namely ‘TGx biomarkers,’ have been reported [3] and
would be useful for better evaluation of drug-elicited toxicities. On the
other hand, public, private and commercial TGx databases have been
developed [1]. Thus, the analytical infrastructures for TGx research
have been maturing considerably.Although bodies of TGx databases and biomarkers are growing
rapidly, the compatibility of microarray data sets obtained from
different studies has been questioned in a number of reports [4,5], a
problem which will hinder efﬁcient utilization of TGx databases and
biomarkers. To address this issue, the MicroArray Quality Control
(MAQC) consortium investigated the compatibility of toxicoge-
nomic data sets for rat livers and concluded that microarray data
sets are more comparable among different studies when the fold
change values of the genes between chemical-treated and
corresponding control groups are used, rather than individual signal
data or statistical P-values [6]. In addition, other reports suggested
that it is beneﬁcial to perform a gene set-level (or pathway-level)
data analysis instead of an individual gene-level analysis when
comparing microarray data obtained from different studies [7,8].
Collectively, when analyzing TGx data using multiple data sets
obtained from different studies, it would be desirable to use fold
change values focusing on certain gene sets, instead of individual
genes.
Recently, we reported a scoring method called the differentially
regulated gene score (D-score), which summarizes the overall gene
expression changing levels focusing on a set of genes using both the
fold change value and data quality information provided by MAS5
algorithm-analyzed GeneChip data [9]. This scoring method is very
simple and consequently it is easy to interpret the biological and
toxicological signiﬁcance of the result. In addition, the D-score is
thought to be more comparable among different microarray
databases, since the score considers the expression ratio of a set of
genes (or toxicogenomic biomarker), not individual genes, be-
tween chemical-treated and vehicle-treated animals. The D-score
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activated biological pathways [9]. However, it would be even more
helpful for toxicologists if the biological signiﬁcance suggested by
the changes in D-scores was interpreted in a context of systems-
level molecular dynamics, namely a ‘Systems Biology’-style data
interpretation.
Systems Biology is an emerging discipline for understanding
organisms in the terms of their biological systems level [10] and the
application of Systems Biology to toxicological research is called
‘Systems Toxicology’ [11]. From a Systems Biology point of view,
biological processes are examined in the framework of pathways or
biological modules which consist of tens or hundreds of molecules,
rather than a single or a few sets of molecules. Usually the biological
interactions among the pathways are presented as a graph in which
the nodes are bio-molecules (e.g. genes, proteins, metabolites or
miRNAs) and the edges are functional relationships among the nodes
(e.g. transcriptional/translational regulation, protein-protein interac-
tion or metabolic reactions) [12]. In particular, inference of a genetic
regulatory network based on microarray data is one of the most
preferred research targets, since it is not only useful for understanding
the molecular mechanisms of biological events but may also lead to
the discovery of novel diagnostic biomarkers in diseased conditions
[13]. While conventional research on genetic regulatory network
analysis has been focused on individual genes [14–16], in the present
study we hypothesized that a gene set-level network analysis would
lead to establishment of more robust and comparable network
structure that can be applicable to microarray data obtained from
different studies. In addition, a retrospective network inference using
a large-scale TGx database may give us information not only for well
investigated pathway–pathway relationships but also for unknown
relationships that may lead to the discovery of novel biomarkers for
toxicity evaluation.
So far, a number of network inference algorithms have been
utilized, such as relevance network (RN), a Gaussian graphical model
(GGM) and Bayesian network (BN) [17]. Each algorithm has its own
pros and cons: for example, RN implements pairwise comparison (e.g.
Pearson's correlation coefﬁcient) which is easy to compute, but RN
cannot distinguish between direct and indirect interactions between
nodes. On the other hand, the GGM algorithm considers a partial
correlation coefﬁcient (PCC), by which direct relationships between
two nodes from indirect ones can be distinguished. According to a
comparative analysis between GGM and RN algorithms, GGM
demonstrated a more stable performance for network inference
compared with RN [17]. On the other hand, a comparison between
GGM and BN algorithms showed that there was insufﬁcient evidence
showing signiﬁcant difference between the two algorithms when
using observational (or “static”) data [17,18] where no interference
experiments were performed. Based on this information, we hypoth-
esized that a GGM algorithm would work sufﬁciently for an
appropriate network structure when performing a retrospective
network inference analysis using an observational TGx data set. In
the present study, we inferred a gene set-level network structure with
a GGM algorithm using the large-scale TGx database system
(Toxicogenomics Project-Genomics Assisted Toxicity Evaluation sys-
tem, TG-GATEs) developed by the government-industry collaborative
research Toxicogenomics Project in Japan (TGP) [19]. The robustness
of the established network structure was investigated using micro-
array data obtained from outside TGP, namely GeneChip data on rat
livers treated with either bromobenzene (BBz) or cycloheximide
(CHX). The established network contained not only well-known
relationships among gene sets or phenotypes but also contained ones
whose biological signiﬁcance is not intuitively clear. It was demon-
strated that the microarray data on BBz- and CHX-treated rat livers
showed good compatibility with the established network, indicating
that the network structure inferred based on the TG-GATEs database
is robust for an external microarray data set. This gene set-levelnetwork inference analysis would lead to better toxicity proﬁling and
may lead to the discovery of novel toxicity biomarkers.
Materials and methods
Development of TG-GATEs database system in TGP
All the animal studies as well as the GeneChip analysis were
supervised and performed by TGP and all the TGx data were organized
and stored in the TG-GATEs database system [19]. The ﬁrst author of
this manuscript (NK) had been working as a member of TGP and
contributed in part to the development of the TG-GATEs database
system.
Animal studies in TGP
The names and dosage levels of the 118 chemicals used in the TGP
in vivo toxicity studies are summarized in Table 1, with detailed
animal study information having been previously described [20].
Brieﬂy, 6-week old male Sprague–Dawley rats (Charles River Japan,
Inc., Kanagawa, Japan) with ﬁve animals per group were used in the
study. Although multiple dosage levels were tested in the TGP in-life
toxicity studies, we used only the highest dosage group data in the
present paper. In the single treatment study, the rats were sacriﬁced
at 3, 6, 9 or 24 h after the treatment of chemical or vehicle. In the
multiple treatment study, the rats were treated with either chemical
or vehicle once daily for 4, 8, 15 or 29 days and were sacriﬁced at 24 h
after the last treatment. The livers were removed at necropsy and
soaked in RNALater (Ambion Inc., Austin, TX) to prevent RNA
degradation. All the experimental protocols for the animal studies
were reviewed and approved by the Ethics Review Committee for
Animal Experimentation of the National Institute of Health Science.
GeneChip analysis in TGP
A detailed procedure for GeneChip analysis was previously
reported [20]. Brieﬂy, three liver samples out of ﬁve were used for
the microarray analysis. Total RNA was isolated using an RNeasy Mini
Kit with Bio Robot 3000 (Qiagen, Inc., Valencia, CA), and 5 μg of the
total RNA was used for cDNA synthesis using T7-(dT)24 oligonucle-
otide primer (Affymetrix Inc., Santa Clara, CA) and SuperScript Choice
System (Invitrogen, Carlsbad, CA). Biotin-labeled cRNA was synthe-
sized using a BioArray High Yield RNA Transcription Labeling Kit
(Enzo Diagnostics, Farmingdale, NY). The hybridization cocktail was
prepared with 10 μg of fragmented cRNA and hybridized to Rat 230
2.0 GeneChip array (Affymetrix, Inc.) at 45 °C for 18 h, followed by
washing and staining by streptavidin-phycoerythrin using Fluidics
Station 400 (Affymetrix, Inc.). The scanned imagewas analyzedwith a
MAS5 algorithm using GCOS software (Affymetrix, Inc.). All the
MAS5-analyzed data were scaled by global normalization.
TGx data sets for network inference
All the GeneChip data and phenotype data (i.e. blood chemistry,
hematology, body weight and organ weight) used for gene set- and
phenotype-level network inference were retrieved from the TG-
GATEs database system (Fig. 1). Although the TG-GATEs system
contains TGx data sets for 150 compounds, it also contains data sets
for 17 proprietary chemicals provided by the participant pharmaceu-
tical companies and those data were excluded from the analysis. In
addition, data sets for 15 chemicals did not have complete data sets
(i.e. 3 animals per group, 8 time points) for the highest dosage group,
either because of an irregular study design or animal death before the
scheduled necropsy time points. Consequently, the data sets for a total
of 118 chemicals were used for network inference (Table 1). These
118 compounds have complete data sets for 8 time points (3, 6, 9 and
24 h for a single treatment study, and 4, 8, 15 and 29 day s for a
repetitive treatment study).
Table 1
Chemical information.
Name Abbreviation Dose
(mg/kg)
Name Abbreviation
Allyl Alcohol AA 30 Ibuprofen IBU
Acetamidoﬂuorene AAF 1000
(300)
Imipramine IMI
Acarbose ACA 1000 Isoniazid INAH
Acetazolamide ACZ 600 Iproniazid IPA
Ajmaline AJM 300 Ketoconazole KC
Amiodarone AM 200 Labetalol LBT
Amitriptyline AMT 150 Lomustine LS
Naphthyl
isothiocyanate
ANIT 15 Hexachlorobenzene HCB
Acetaminophen APAP 1000 Haloperidol HPL
Allopurinol APL 150 Hydroxyzine HYZ
Aspirin ASA 450 Methyldopa MDP
Azathioprine AZP 30 Mefenamic Acid MEF
Benzbromarone BBr 200 Mexiletine MEX
Bromobenzene BBZ 300 Metformin MFM
Bucetin BCT 2000
(1000)
Methapyrilene MP
Bendazac BDZ 1000
(300)
Methyltestosterone MTS
Bromoethanamine BEA 60 (20) Methimazole MTZ
Benziodarone BZD 300 Moxisylyte MXS
Caffeine CAF 100 Nitrofurantoin NFT
Captopril CAP 1000 Nitrofurazone NFZ
Carboplatin CBP 100 (10) Nicotinic acid NIC
Carbamazepine CBZ 300 Nifedipine NIF
Carbon
tetrachloride
CCL4 300 Nimesulide NIM
Cloﬁbrate CFB 300 Phenylanthranilic
acid
NPAA
Chlorpheniramine CHL 30 Omeprazole OPZ
Cimetidine CIM 1000 Papaverine PAP
Chlormadinone CLM 2000
(1000)
Phenobarbital PB
Cephalothin CLT 2000 Phenacetin PCT
Coumarin CMA 150 Penicillamine PEN
Chlormezanone CMN 500 Perhexiline PH
Chloramphenicol CMP 1000 Phenylbutazone Phb
Colchicine COL 15 (5) Phenytoin PHE
Cyclophosphamide CPA 15 Pemoline PML
Clomipramine CPM 100 Promethazine PMZ
Chlorpropamide CPP 300 Propylthiouracil PTU
Ciproﬂoxacin CPX 1000 Quinidine QND
Cyclosporine A CSA 300
(100)
Ranitidine RAN
Diclofenac DFNa 10 Rifampicin RIF
Diltiazem DIL 800 Sulpiride SLP
Disopyramide DIS 400 Sulfasalazine SS
Danazol DNZ 2000
(1000)
Simvastatin SST
Disulﬁram DSF 600 Sulindac SUL
Dantrolene DTL 250 Thioacetamide TAA
Diazepam DZP 250 Tannic acid TAN
Ethambutol EBU 1000 Terbinaﬁne TBF
Ethinylestradiol EE 10 Tetracycline TC
Erythromycin
ethylsuccinate
EME 1000 Ticlopidine TCP
Enalapril ENA 600 Theophylline TEO
Ethionine ET 250 Tiopronin TIO
Ethanol ETN 4000 Tolbutamide TLB
Etoposide ETP 1000
(30)
Trimethadione TMD
Famotidine FAM 1000 Tamoxifen TMX
Fenoﬁbrate FFB 1000 Triamterene TRI
Fluphenazine FP 20 Thioridazine TRZ
Flutamide FT 150 Triazolam TZM
Furosemide FUR 300 Vitamin A VA
Glibenclamide GBC 1000 Vancomycin VMC
Griseofulvin GF 1000 Valproic Acid VPA
Gentamicin GMC 100 Wy-14643 WY
Parenthesis: dose level in repetitive treatment study.
Fig. 1. Overview of network inference. The major objective of the present study was to
develop a gene set- and phenotype-level network based on TG-GATEs, a large-scale
toxicogenomics database developed by the government–industry collaborative
Toxicogenomics project in Japan (TGP). Both microarray and phenotype (i.e. blood
chemistry, hematology, body weight and organweight) data for rats treated with one of
118 chemicals with 8 time observational points were used in the present study. The
gene expression change level was evaluated by calculating the D-score using 58 gene
lists (Table 2), followed by z-score transformation. The phenotype changing level was
evaluated by the change ratio between chemical-treated and vehicle-treated rats,
followed by z-score transformation. The gene set- and phenotype-level network was
inferred using a Gaussian graphical model (GGM) algorithm. The robustness of the
established network structure was investigated using microarray data on rat livers
treated with either bromobenzene or cycloheximide obtained outside TGP.
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Drug-elicited changes in gene expressions and phenotypes were
evaluated by scoring their changing levels. The scores were calculated
based on average data of each chemical-treated group (3 animals per
group) and the calculated scores were subjected to network inference.
A summarized analytical ﬂow is presented in Fig. 1.
Scoring a gene set-level expression change
For evaluation of gene set-level expression changes, the D-score [9]
was calculated for a total of 58 ‘biomarker’ gene sets (Table 2), all of
whichwere selected based ongene annotation information provided by
Affymetrix Inc. except for two biomarker gene sets whose expression
levels are reported to be closely associated with non-genotoxic
carcinogenesis [21] or glutathione depletion [22]. Detailed information
for the 58 gene lists is provided in Supplementary Table 1. A detailed D-
score calculation procedure is described in the previous paper [9].
Brieﬂy, the signal log ratio (SLR, base 2) was calculated by dividing the
mean signal value of the chemical-treated group by that of the
corresponding vehicle-treated group, and the Presence ratio (PR) was
determined by dividing the number of the Presence Call given for both
chemical- and vehicle-treated by the total number of chemical-treated
and vehicle-treated animals. For example, if all 3 of the chemical-treated
animals gave Presence and all 3 of the vehicle-treated animals gave
Absence Calls, respectively, the PR is calculated as (3+0)/(3+3)=0.5.
Assuming that a gene set X consists of i probe sets (x1, x2, x3,…, xi−1, xi),
the calculated SLRs were given as (SLR1, SLR2, SLR3,…, SLRi−1, SLRi) and
PRs were given as (PR1, PR2, PR3, …, PRi−1, PRi). Let the sum of
(SLR1×PR1, SLR2×PR2, SLR3×PR3,…, SLRi−1×PRi−1, SLRi×PRi) divided
by i and the sum of ([SLR1×PR1]2, [SLR2×PR2]2, [SLR3×PR3]2, …,
[SLRi−1×PRi−1]2, [SLRi×PRi]2) divided by i be indexes for “overall
direction of the expression change per probe set” and for the “overall
magnitude of the expression change per probe set” of the Gene set X
Table 2
Summary of gene list.
Node name Number of
probe sets
Description
ABC_transporter 50 ABC transporter family
Akr 20 Aldo-keto reductase family
AP1 11 Components of AP1 complex
Bcl 21 Mitochondrial apoptosis and BCL2-
related genes
Caspase 19 Caspase family
Cebp 9 CCAAT/enhancer binding protein
family
Cell_proliferation 22 Cell proliﬁration-related genes
Chemokine 61 Chemokines
Cholesterol_synthesis 19 Genes involved in cholesterol synthesis
Cyclin 35 Cyclin family
Cyp1a1 3 Cyp1a1 and aryl hydrocarbon
receptor (AhR) genes
Cyp1a2 1 Cyp1a2 gene
Cyp1b1 1 Cyp1b1 gene
Cyp2b 5 Nuclear receptor CAR and Cyp2b
family genes
Cyp2c 7 Cyp2c family genes
Cyp3a 5 Nucelar receptor PXR and Cyp3a
family genes
Cyp4a 5 Cyp4a family genes
DNA_damage 10 DNA damage-responsive genes
ER_stress 3 Endoplasmic reticulum stress-
responsive proteins
Fgf 38 Fibroblast growth factor genes
Glutathione_homeostasis 11 Genes related with glutathione
synthesis and reduction
Glycolysis 46 Genes involved in glycolysis
Gst 19 Glutathione S-transferase family
Hemoglobin 9 Hemoglobin genes
Hsp 41 Heat shock protein genes
Hypoxia 6 Genes associated with hypoxia
Igf 30 Insulin-like growth factor genes
IL_receptor 33 Interleukin receptor genes
Inﬂammation 19 Inﬂammation-related genes
Interleukin 29 Interleukin genes
Ketone_body 5 Genes involved in ketone body
metabolism
LXR 16 Genes regulated by nuclear receptor
LXR
Misc_GF 28 Miscellaneous growth factors
MMP 30 Matirx metalloprotease genes
Mt_electron 40 Genes related with mitochondrial
electron transport
Mt_genome 5 Genes encoded by mitochondrial
genome
Mt_ribosome 101 Genes encoding mitochondrial
ribosomes
NFkB 15 NF-kappa B-related genes
Organic_cation_transporter 11 Organic cation transporter genes
Oxidative_stress 20 Genes associated with oxidative
stress
PDGF 9 Platelet derived growth factor-
related genes
Phorone_GSH_depletion 161 Glutathione depletion-responsivve
genes
PP 43 Peroxisome-localized proteins
PPAR 5 Peroxisome proliferator activated
receptor family
Proteasome 61 Genes related with proteasome
component
Ribosome 125 Ribosomal genes
Slc 334 Solute carrier family
Slco 19 Solute carrier organic anion
transporter family
Stellate 6 Genes associated with stellate cell
activation
Steroid_hormone 11 Genes related with steroid hormone
synthesis / metabolism
Sterol_related 67 Genes related with steroid
metabolism
TGF 17 Transforming growth factor (TGF)
genes
Table 2 (continued)
Node name Number of
probe sets
Description
TGF_b 43 TGF beta signaling-associated genes
TNF 10 Tumor necrosis factor-related genes
Carcinogenesis 112 Genes associated with non-genotoxic
carcinogenesis
Ubiquitin 230 Genes related with ubiquitin
conjugation
Ugt 10 UDP glucuronosyltransferase family
Vegf 4 Vascular endothelial growth factor
genes
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indexes shown above by a ×100 scaling factor. The calculated D-scores
were then transformed into z-scores by the following equation:
Z = X − μð Þ = σ
where X is the raw D-score, μ is the mean of the D-score for all the
chemicals and σ is the standard deviation of the D-score for all the
chemicals.Table 3
Summary of the phenotype information.
Node name Description
Organ/body weight
TERMINAL_BW Terminal body weight
LIVER_WT Liver weight
KIDNEY_TOTAL_WT Total kidney weight
KIDNEY_R_WT Relative right kidney weight
KIDNEY_L_WT Relative left kidney weight
LIVER_WT_PER_BW Relative liver weight
KIDNEY_TOTAL_WT_PER_BW Relative total kidney weight
KIDNEY_R_WT_PER_BW Relative right kidney weight
KIDNEY_L_WT_PER_BW Relative left kidney weight
Hematology
RBC Red blood cell count
Hb Hemoglobin
Ht Haematocrit
MCV Mean corpuscular volume
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
Ret Reticulocytes
Plat Platelet
WBC White blood cell
Neu Neutrophil
Mono Monocytes
Lym Lymphocytes
PT Prothrombin time
APTT Activated partial thromboplastin time
Fbg Fibrinogen
Blood chemistry
ALP Alkaline phosphatase
TC Total cholesterol
TG Triglycerides
PL Phospholipids
GLC Glucose
BUN Blood urea nitrogen
CRE Creatinine
Na Sodium
K Potassium
Cl Chloride
Ca Calcium
IP Inorganic phosphorous
TP Total protein
RALB Rat albumin
A_G Albumin/globulin ratio
AST Aspartate aminotransferase
ALT Alanine aminotransferase
LDH Lactate dehydrogenase
Fig. 2. Correlation among gene sets and phenotypes. (A) Heat map presentation of gene set- and phenotype-level scores. D-score and changing ratio values between chemical-
treated and vehicle-treated rats were calculated for gene set and phenotype data, respectively, andwere rank-ordered. Black andwhite in the heat map indicate that the rank order is
close to 1 and 944, respectively. Descriptions of the labels for each column can be found in Tables 2 and 3. (B) Frequency distribution of partial correlation coefﬁcients (PCC) between
nodes. A total of 335 edges whose |PCC|N0.065 satisﬁed a false discovery ratio q-value less than 0.01, and these edges were used for network analysis.
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Fig. 3. Network inferred based on TG-GATEs database. Gene set- and phenotype (blood chemistry, hematology, body weight and organ weight)-level changes were evaluated on
toxicogenomics data sets for rats treated with one of the 118 chemicals (8 time points) by calculating the z-scored D-score and z-scored changing ratio between chemical-treated
and vehicle-treated rats, respectively. Relationships among the gene sets and phenotype data were evaluated by a partial correlation coefﬁcient (PCC) using a Gaussian graphical
model algorithm and the edges with statistically signiﬁcant PCC were used for drawing the network using Cytoscape software. Edges with purple and green indicate positive and
negative relationships, respectively.
Fig. 4.Mean number of edges per node. Number of edges per node for blood chemistry
and hematology (N=33), body and organ weights (N=9) and gene set (N=58) are
presented. Gene set showed signiﬁcantly (Pb0.05 by a one-way ANOVA followed by a
Tukey's post hoc test) greater number of edges per node compared with blood
chemistry and hematology.
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A total of 42 phenotype data sets (18 blood chemistry data sets, 15
hematology data sets, and 9 of body and organ weight data sets) were
subjected to network inference (Table 3). For evaluation of the
phenotype-level changes, the changing ratio value was calculated by
dividing the mean of the chemical-treated group by that of the
corresponding vehicle-treated group, followed by transformation into
a z-score.
Network inference
The gene set- and phenotype-level network structure was inferred
using GeneNet software [23] implemented on the statistics software R
(CRNA project) [24]. A GeneNet package was obtained from the
Bioconductor project website (http://www.bioconductor.org/) [25].
A time-course D-score data set of each chemical-treated group using
58 biomarker gene sets was prepared using a ‘longitudinal package’
(http://cran.r-project.org/web/packages/longitudinal/), and a ggm.
estimate.pcor() function provided in the GeneNet package (http://
cran.r-project.org/web/packages/GeneNet/) was implemented for
network inference by the GGM algorithm. The statistical signiﬁcance
of each edge between nodes (i.e. gene set and phenotypes) was
estimated by ggm.test.edges() function provided in the GeneNet
package, where the false discovery rate (q-value) of PCC is calculated
for each edge. In the present study, edges with a q-valueb0.01 were
considered signiﬁcant and were used for further analysis. Cytoscape
Fig. 5. Representative interactions. (A) Glucose-centered network. Blood glucose level (GLC) and its ﬁrst neighbor nodes were highlighted from the whole network presented in Fig.
3. Numbers on the edges represent partial correlation coefﬁcients between nodes. Positive and negative correlations between nodes are colored as purple and green, respectively. (B)
LDH-centered network. (C) Relative liver weight-centered network.
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value given for each edge.
Veriﬁcation of the inferred network structure
To investigate if the inferred network structure established based
on the TG-GATEs database could be applicable to external micro-
array data sets, we prepared microarray data of bromobenzene
(BBz) or cycloheximide (CHX)-treated rat livers and D-scores for 58
gene sets were calculated. The D-scores for a total of 31 gene sets
exhibiting either greater than 20 or less than −20 for at least one
data set in the BBz- or CHX-treated groups were subjected to the
following analysis.
Animal studies for BBz and CHX treatments
BBz and CHX were purchased from Sigma Aldrich (St. Louis, MO,
USA) and 9-week-old male F344/DuCrj rats (Charles River Japan Inc.,
Yokohama, Japan) were used for the studies. For the BBz treatment,
animal groups consisting of four rats were intraperitoneally admin-
istered with BBz (300 mg /kg body weight per day) or corn oil as a
vehicle control. The animals were killed under ether anesthesia at 2, 6,
12 and 24 h after the BBz treatment and the liver samples were snap-
frozen and stored at−80 °C until use. For the CHX treatment, the liver
samples were obtained 1 h, 2 h and 6 h after the intravenous
treatment of CHX (6mg/kg bodyweight). Detailed information on the
CHX animal study is described in the previous report [27]. The
experimental protocols for these studies were approved by the Ethics
Review Committee for Animal Experimentation of Daiichi Sankyo Co.,
Ltd.
GeneChip analysis for BBz- or CHX-treated rat livers
For both the BBz and CHX treatment studies, the liver sampleswere
homogenized with the RLT buffer supplied in the RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) and the total RNA was isolated according
to the manufacturer's instructions. A hybridization cocktail wasprepared with 15 μg of fragmented cRNA and hybridized to Rat 230
2.0 GeneChip array (Affymetrix, Inc.) at 45 °C for 18 h, followed by
washing and stainingwith streptavidin-phycoerythrin using a Fluidics
Station 400 (Affymetrix, Inc.). Microarray image data were analyzed
with the MAS5 algorithm (Affymetrix Inc., Santa Clara, CA, USA). All
the MAS5-analyzed data were scaled by global normalization.
Statistical analysis
The number of edges per node for blood chemistry/hematology
(N=33), organ/body weight (N=9) and gene set (N=58)
calculated by GeneNet software was subjected to a one-way
ANOVA followed by a Tukey's post hoc test using GraphPad Prism
4 (GraphPad Software, La Jolla, CA), and Pb0.05 was considered
statistically signiﬁcant.Results
General proﬁle of the established gene set-level network
All the PCC values between nodes are presented in Supplementary
Table 2. Representative gene set–phenotype relationships which
exhibited high PCC, such as the ones between PDGF gene and ALT
(PCC=0.124), Glycolysis genes and GLC (PCC=0.108), or Gst genes
and relative liver weight (PCC=0.114), are presented as a heat map
in Fig. 2A. The distribution of PCC values for all the gene set- and
phenotype-level relationships is presented in Fig. 2B and a total of 335
relationships (edges) out of 4950 showed statistically signiﬁcant PCC
values (estimated with a False Discovery Rate q-valueb0.01). All the
nodes (i.e. 58 gene sets plus 42 phenotypes) with the 335 statistically
signiﬁcant edges are presented as a network graph in Fig. 3, where
positive and negative relationships are colored purple and green,
respectively. Next, the number of edges per node was investigated for
blood chemistry, hematology, body weight, organ weights and gene
set, and it was revealed that the number of edges per node was
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hematology (Fig. 4).
Biological signiﬁcance of the established network
As examples of gene set–phenotype relationships, GLC, LDH and
relative liver weight-centered subnetworks with their 1st neighbored
nodes are highlighted in Fig. 5. GLC showed the strongest direct
positive correlation with Glycolysis genes (PCC=0.108) and direct
negative correlation with Cholesterol synthesis genes (PCC=−0.074)
(Fig. 5A). GLC also showed direct correlation with PPAR genes
(PCC=0.080), IP (PCC=0.066) and BUN (PCC=0.081). On the
other hand, LDH showed high direct positive correlations with AST
and ALT (PCC=0.181 and 0.079, respectively) (Fig. 5B). In addition,
LDH showed a couple of strong correlations with gene sets such as
Chemokine genes (PCC=0.188), Bcl genes (PCC=0.110) and Inﬂam-
mation genes (PCC=0.087). Regarding relative liver weight, the
following reasonable relationships were observed: strong positive
and negative relationships with liver weight (LIVER_WT,
PCC=0.407) and terminal body weight (TERMINAL_BW,
PCC=-0.096), respectively (Fig. 5C). In addition, the relative liverFig. 6. Time-course of D-score proﬁle for bromobenzene-treated rat liver. Rats were treated
treatment, and GeneChip analysis was conducted. Red and blue colors indicate high and low
increased, indicating that the genes associated with DNA damage were overall up-regulated
were increased, and those for Cyp1a1 and Cyp2b genes were increased as well. At 12 h, the inc
were observed, suggesting that the increased D-score for DNA damage genes triggered at
addition, the increase in the D-scores for Cyp1a1 and Cyp2b genes disappeared at 12 h, and in
respectively, were increased at 12 h. Furthermore, the D-score for Cholesterol synthesis genes
scores for Cebp and NfkB genes were increased and those for LXR and Slco genes were decrea
applicable to microarray data on BBz-treated rat liver which was obtained from outside TGweight showed positive correlations with Gst and LXR genes
(PCC=0.114 and 0.093, respectively), and negative correlation with
Interleukin genes (PCC=-0.068).
Veriﬁcation of D-score network with data sets from outside TG-GATEs
To verify the robustness of the network structure inferred based on
TG-GATEs, we investigated time-course gene expression proﬁles on
rat livers treated with CHX or BBz. First, D-scores for CHX- or BBz-
treated rats using 58 gene sets were obtained and the gene sets whose
D-scores were greater than 20 or smaller than−20 for at least at one
time point were selected and subjected to further analysis. Thirty-one
gene sets were selected in this process, and were re-organized as a
subnetwork (Figs. 6 and 7). All the D-scores for BBz- or CHX-treated
rats are presented in Supplementary Table 3.
BBz-treated rat liver
The time-course of the D-score proﬁle for the BBz-treated rat
liver is presented in Fig. 6. The D-score for DNA damage genes was
ﬁrst increased at 2 h after the treatment. At 6 h, D-scores for
Glutathione depletion and Oxidative stress genes were increased, andwith 300 mg/kg bromobenzene, the livers were collected at 2, 6, 12 or 24 h after the
D-scores for the gene sets, respectively. At 2 h, the D-score for DNA damage genes was
at this time point. At 6 h, D-scores for Phorone glutathione depletion and Oxidative stress
reased D-scores forHSP, Carcinogenesis, Glutathione homeostasis, ER stress and AP1 genes
2 h affected its neighbored nodes and the area of activated nodes was propagated. In
stead those for Akr and Gst genes, which are ﬁrst neighbors of Cyp1a1 and Cyp2b genes,
was decreased, which has a negative correlation with DNA damage genes. At 24 h, the D-
sed. Overall, the established network inferred based on the TG-GATEs data set was well
P.
Fig. 7. Time-course of D-score proﬁle for cycloheximide-treated rat liver. Rats were intravenously treated with 6 mg/kg bromobenzene, the livers were collected at 1, 2 or 6 h after
the treatment, and GeneChip analysis was conducted. At 1 h after the treatment, increased D-scores were observed for ER stress, DNA damage, Carcinogenesis, AP1, Cholesterol
synthesis, Interleukin and Glutathione depletion genes, followed by Cebp- and NFkB genes at 2 h, which are adjacent to ER stress- and AP1 genes on the network. At 6 h, the area of
increased D-scores was propagated as far as IL receptor and Caspase genes on the network. Again, the established network inferred based on the TG-GATEs data set were well
applicable to microarray data on CHX-treated rat livers which were obtained from outside TGP.
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for HSP, Carcinogenesis, Glutathione homeostasis, ER stress and AP1
genes were increased, suggesting that the increase in the D-score for
DNA damage genes triggered at 2 h affected its neighbored nodes
and the activation of the neighbored gene sets propagated
sequentially. In addition, the increased D-scores for Cyp1a1 and
Cyp2b genes disappear at 12 h, but instead the D-scores for Akr and
Gst genes, which are ﬁrst neighbors of Cyp1a1 and Cyp2b genes,
respectively, were increased at 12 h. Furthermore, a decreased D-
score was observed for Cholesterol synthesis genes, which has a
negative correlation with DNA damage genes that showed an
increased D-score as early as at 2 h. Eventually, at 24 h, D-scores
for Cebp and NfkB genes were increased and those for LXR and Slco
genes were decreased.
CHX-treated rat liver
The time-course of D-score proﬁle for the CHX-treated rat liver is
presented in Fig. 7. A number of gene sets showed an increased D-
score at 1 h after the treatment, such as ER stress, DNA damage,
Carcinogenesis, AP1, Cholesterol synthesis, Interleukin and Glutathione
depletion genes. At 2 h, increased D-scores were observed for Cebp-
and NFkB genes, which are adjacent to ER stress- and AP1 genes on the
network, and a decreased D-score was observed for Cyp1a2 gene. At
6 h, the area of increased D-scores was propagated as far as IL receptor
and Caspase genes on the network. In addition, a decreased D-scorewas observed for Cyp2b gene, which is adjacent to Cyp1a2 gene which
showed decreased D-score at 6 h.
Discussion
Network inference based on gene set-level data, not individual
gene-level data, was utilized in the present study. At least two
advantages are expected by conducting a gene set-level network
analysis. First, it is reported that a gene set-level (or biological
pathway-level) analysis is usually more robust and comparable for
microarray data sets obtained from different studies [7,8]. Second, a
GGM algorithm, used for network structure inference in the present
study, would work better by reducing the number of inputs for
calculation by grouping a set of genes from a microarray data set
because when using a GGM algorithm the number of samples N
should be large enough compared with the number of variables p (e.g.
expression level data for individual genes), which is one of the serious
problems when handling microarray data where tens of thousands of
pieces of gene expression data are obtained at a time. While a number
of studies have tried to avoid the p≫N problem when analyzing
microarray data [28,29], gene set-level analysis can circumvent this
issue because the number of D-score-summarized data (p=58 in this
study) is considerably smaller than the number of samples (N=118
chemicals×8 time points=944 in this study). Thus, gene set-level
network inference has clear advantages in terms of both data
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large-scale microarray data sets.
The inferred network presented in Fig. 3 possessed a couple of
interesting characteristics. First, the number of edges per node
indicated that the nodes of the gene sets had a greater number of
edges compared with those for blood chemistry and hematology (Fig.
4), suggesting that the gene expression was more actively regulated
compared with the blood chemistry and hematology parameters, and
that gene expression analysis may give us more clues into the
mechanisms of drug-elicited toxicity. Second, the established network
exhibited a number of reasonable biological relationships between
nodes. For example, blood glucose level (GLC) showed the strongest
correlation with Glycolysis genes (Fig. 5A). In addition, GLC showed
strong correlationwith PPARα genes, which is supported by a previous
study reporting that PPARα regulates glycolytic gene expression [30].
On the other hand, LDH showed strong correlation with AST and ALT
(Fig. 5B), all of which indicate the incidence of drug-elicited liver cell
injury. As well, LDH showed correlations with inﬂammation-associ-
ated gene sets such as AP1, Inﬂammation and Chemokine genes,
suggesting close relationships between cell injury and inﬂammatory
response in the liver. Furthermore, LDH and Bcl genes showed a direct
relationship with each other, for which the biological signiﬁcance is
supported by previous studies showing that Bcl genes are associated
with either a pro- or an anti-apoptotic reaction accompanied by
incidences of cell injury [31]. Collectively, these results demonstrate
that the gene set- and phenotype-level network analysis performed in
the present study successfully extracted meaningful biological
relationships from complicated TGx data sets. On the other hand,
the biological signiﬁcance of some of the relationships, such as ones
between GLC and BUN, GLC and IP (Fig. 5A), relative liver weight and
Gst genes or relative liver weight and LXR genes (Fig. 5C), was not
intuitively clear and these relationships might be less relevant in
terms of toxicology. However, because these relationships were
suggested based on large-scale TGx data sets, it is worth the effort to
investigate them. This may lead to a better understanding of the
molecularmechanisms of toxicity and in turn to the discovery of novel
toxicity-associated biomarkers, as suggested in a previous report [32].
Although TGx research is thought to be quite useful for evaluating
the molecular mechanisms of toxicities, the compatibility of the
microarray data sets among sets obtained from different studies has
been questioned in a number of reports [4,5] and this problem may
ﬂaw the efﬁcient utilization of the TGx database and biomarkers. To
address the robustness of the established network structure in the
present study, we investigated the compatibility of microarray data on
rat livers treated with either BBz or CHX that were obtained outside
TGP. BBz and CHX are reported to cause liver cell injury through
distinct molecular mechanisms: when overdosed BBz causes centri-
lobular necrosis in the hepatocytes through the generation of reactive
metabolites [33], and CHX causes apoptosis in the hepatocytes,
possibly mediated through ER stress [27].
In the BBz-treated rat liver, the D-score for DNA damage genes
showed an increase at 2 h after the treatment and that for Oxidative
stress genes showed a slight increase at this time point (Fig. 6). At 6 h,
the D-score for Phorone GSH depletion genes, which are a ﬁrst neighbor
node for both DNA damage and Oxidative stress genes, showed a
marked increase, and those for Cyp1a1 and Cyp2b genes showed a
tentative increase, while that of Cholesterol metabolism genes showed
a marked decrease. These activated nodes are indicative of the
generation of reactive metabolites in the liver and consequent
oxidative stress and glutathione depletion at 6 h. At 12 h, the area
of high-D-score nodes propagated to Glutathione homeostasis, Akr, ER
stress, AP1 and Gst genes, all of which suggest a response against
oxidative stress and dysfunction of cellular macromolecule turnover.
On the other hand, the D-score for LXR genes showed a decrease at
12 h. Eventually, at 24 h the area of the increased D-score was
extended as far as Cebp and NFkB genes on the network, which areassociated with tissue repair and stress response, respectively. On the
other hand, at 24 h, the area of decreased D-score extended to Slco,
Ketone body and Glycolysis genes, which are the nearest neighbors of
LXR genes, whose D-score was decreased at 12 h. It should be noted
that most of the time-course increases and decreases in the D-scores
were propagated through positively correlated nodes, such as the
ones between DNA damage and Phorone GSH depletion genes
(increased D-score) or the one between LXR and Slco (decreased D-
score). In addition, the signs of the D-score for DNA damage and
Cholesterol synthesis genes (2–24 h) or Oxidative stress and Igf genes
(24 h) were opposite, which is reasonable considering that they have
negative relationships with each other. These results indicate that the
established network structure based on the TG-GATEs data set was
robust enough to be comparable with the microarray data on BBz-
treated rat liver obtained outside TGP, even though the strain and age
of the rats used in the in-life studies were different from those used in
the TGP studies.
In the CHX-treated rats, the D-scores for a number of gene sets
were increased as early as at 1 h after the treatment (Fig. 7). Similar to
the BBz study, the time-course changing proﬁle of the D-scores
showed sequential propagation through neighbored nodes on the
network. This result further supports the notion that the gene sets as
well as the established gene set-level subnetwork highlighted in Figs.
6 and 7 would be useful biomarkers for evaluating BBz- and CHX-
induced molecular mechanisms of toxicities. Accumulation of such
toxicity-associated gene set-level subnetwork would aid efﬁcient
proﬁling of TGx data set and may lead to identiﬁcation novel
biomarker candidates.
Although the network inference using gene set- and phenotype-
level data appeared to work well in the present study, a number of
points should be considered to reﬁne the analytical system. First, in
the present study, the gene set- and phenotype-level network was
inferred based only on passively observed TGx data sets and therefore
the network inference was totally retrospective. According to a
previous study, it was demonstrated that the BN algorithm out-
performed GGM and RN when using an interventional data set [17]
and therefore BN could infer a better network structure if an
appropriate interventional data set were prepared. However, it is
difﬁcult to prepare interventional data sets for gene set-level analysis
compared with single gene-level analysis, since it is not easy to
exclude the total effects of a set of genes when a single gene can be
knocked down, completely excluding its effect. Nonetheless, the
structure of a gene set-level network will be more sophisticated if a
set of appropriate interventional data sets can somehow be prepared.
Second, an appropriate study design for collecting the TGx data set
will be a crucial factor for network inference. A high dose chemical
exposure elicits a mixed response of primary, secondary and more
downstream reactions in the body and therefore ﬁnding the
appropriate dosage level and time points for sample collection by
dissecting such complicated biological reactions will be crucial for
better network inference.
Third, the gene set used for proﬁling the activities of biological
pathways is tissue- and species-speciﬁc and therefore needs to be
prepared and optimized case by case. It must be emphasized that the
gene set-level network established in the present study is valid only
for microarray data on rat livers but not for any data collected from
other organs (e.g. kidney, muscle, adrenal grand, etc.) or other species
(e.g. mice, dogs, monkeys, humans, etc.). We need to establish ﬁt-to-
purpose gene sets for appropriate network inference to better utilize
the TGx data sets for toxicity evaluation. In other words, comparative
analysis on species-speciﬁc network structures may give us new
insight into species differences in drug-elicited toxicities.
Finally, reﬁnement of the scoring algorithms will dramatically
affect the network structure. Although the D-score can capture the
general tendency of gene expression changing direction and the
changing level of a gene set [9], the calculated score is highly
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algorithms such as Gene Set Enrichment Analysis [34] will provide
opportunities to reveal novel interactions between gene sets and
phenotypes.
In conclusion, we established a gene set- and phenotype-level
relational network using TG-GATEs, a large-scale TGx database. The
subnetwork structure associated with BBz- and CHX-induced toxi-
cities appears to be robust between TG-GATEs and outside data sets.
Accumulation of such robust gene sets with toxicity-associated
subnetwork structures supported by veriﬁcation data sets will not
only be useful for efﬁcient toxicity characterization using TGx data but
will also be helpful for discovering unknown relationships among
gene sets, which may lead to a better understanding of the molecular
mechanisms of drug-elicited toxicities. For the establishment of a
better biological network model, improvement of the computational
algorithms and biomarker gene sets as well as the database quality
should be continued.
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